Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback